Pharmacologic Stress Testing Technique

  • Author: David Akinpelu, MD, FACP; Chief Editor: Eric H Yang, MD  more...
 
Updated: Aug 05, 2016
 

Approach Considerations

In pharmacologic stress testing, the patient reclines while the pharmacologic agent is injected through an IV line. A nuclear tracer is injected through the IV. Blood pressure, heart rate, and ECG are monitored before, during, and after the test, and imaging is obtained at specified times.

Additional imaging may be considered. Software fusion of coronary computed tomography angiography (CCTA) and single photon emission computed tomography (SPECT) images allows for a comprehensive, noninvasive assessment of coronary artery disease (CAD). According to a study by Pazhenkottil et al, hybrid SPECT/CCTA images have a demonstrated synergistic prognostic value. The annual rate of death/myocardial infarction among patients who underwent hybrid imaging was 6%, 2.8%, and 1.3% for patients with matched, unmatched, and normal defect findings, respectively.[4] Stress imaging by MRI with strain encoding improves predictive accuracy of coronary events and stenoses at catheterization even further. In a 28-month follow up, MRI with strain encoding improved sensitivity from 84% to 96% (p< 0.001) with an insignificant drop in specificity (88% vs. 94%).[10] Various pharmacologic agents are used for cardiovascular stress testing and are usually used in combination with radionuclideisotopesthataretakenupby the myocardium during routine testing. The common ones are discussed below.

Next

Adenosine Technique

Dosing and practical considerations

The use of adenosine requires an infusion pump that delivers the dose (140 mcg/kg/min) over a 6-minute period. The patient should have an intravenous line with a 3-way stopcock or should have 2 intravenous lines. If one intravenous line is used, take care to inject the radiopharmaceutical slowly because a bolus or any forceful injection will cause an abrupt increase in the infusion rate of the adenosine running through the same line. This can lead to significant AV nodal block. ECG monitoring of the vital signs is necessary as with exercise stress testing.

Adenosine is infused at a rate of 140 mcg/kg/min for 6 minutes. At the 3-minute mark, the stress radiopharmaceutical is injected and the infusion is continued for 3 more minutes. Some have suggested that patients determined to be at high risk for complications (eg, questionable history of asthma, hypotension, recent ischemic event, severe bradycardia) should undergo an incremental 7-minute adenosine protocol. This protocol starts at 50 mcg/kg/min and increases to 75, 100, and 140 mcg/kg/min at 1-minute intervals followed by injection of the stress radiopharmaceutical at 1 minute after the highest tolerated dose.

The test continues for 3 minutes following injection of the radiopharmaceutical. Unlike dipyridamole, the effect of adenosine dissipates promptly with discontinuation of the infusion. Thus, the infusion must continue during stress imaging until the imaging is completed, whereas for dipyridamole, imaging may follow but in a limited time window. For a stress/rest protocol, adenosine does not require reversal, whereas dipyridamole requires theophylline administration to assure prompt reversal of its stress effects.

Early termination indications

Early termination indications include the following:

  • Severe hypotension (SBP < 90 mm Hg)
  • Symptomatic Mobitz-I second-degree heart block
  • Mobitz-II or third-degree heart block
  • Bronchospasm
  • Severe chest pain associated with ECG changes (>2 mm ST depression or any ST elevation in a non–Q-wave lead): In most cases, discontinuation of the adenosine infusion is followed by a prompt (< 1 min) resolution or improvement of the adverse effect. In rare cases, aminophylline may be required.

Adenosine-walk protocol

For patients who are able, combined low-level treadmill exercise during adenosine infusion has been demonstrated in several reports to be associated with a significant decrease in the frequency of adverse effects (eg, flushing, nausea, headache). In addition, less-symptomatic hypotension and bradycardia occur. These studies have also uniformly reported improved image quality, as demonstrated by an increased target-to-background ratio.

An additional advantage is that simultaneous low-level exercise allows for immediate imaging, as would be performed with exercise stress testing. This is due to the peripheral vasodilation and splanchnic vasoconstriction induced by exercise.

Previous
Next

Dipyridamole (Persantine) Technique

Dosing and practical considerations

The standard dose of dipyridamole 0.56 mg/kg infused over 4 minutes.

Dipyridamole should be infused via an infusion pump over 4 minutes. However, some choose to infuse the dipyridamole by hand, which is also acceptable. The radiopharmaceutical is then injected 3-5 minutes following the completion of the dipyridamole infusion.

Perform a standard ECG and monitoring of the vital signs as with exercise stress testing until the hemodynamic effects of dipyridamole have resolved.

Dipyridamole-walk protocol

The protocol is similar to that of adenosine; however, the treadmill portion does not begin until 1 minute prior to the injection of the radiopharmaceutical (after completion of the infusion of dipyridamole) and should be continued for at least 2 minutes after the injection of the radiopharmaceutical.

Previous
Next

Dobutamine Technique

Dosing and practical considerations

Dobutamine is infused in incremental doses starting at 5 mcg/kg/min for 3 minutes. Then, 10, 20, 30, and 40 mcg/kg/min are administered until the stress end point is reached. The end points are similar to those of exercise stress testing (eg, target heart rate, chest pain with ECG changes, hypotension).

Dobutamine must be infused using an infusion pump. The patient should have an intravenous line with a 3-way stopcock or should have 2 intravenous lines. If 1 intravenous line is used, take care to infuse the radiopharmaceutical slowly because a bolus or forceful injection will cause an abrupt increase in the infusion rate of the dobutamine running through the same line, which can lead to significant tachycardia, hypotension, and myocardial ischemia. Perform standard ECG and blood pressure monitoring as with exercise stress testing.

Dobutamine is infused at a rate of 5 mcg/kg/min for 3 minutes, followed by infusion of 10, 20, 30, and 40 mcg/kg/min each at 3 minutes until a target heart rate is achieved. If the target heart rate is not achieved, atropine can be administered (as much as 2 mg). Once the target heart rate is achieved, the radiopharmaceutical is injected and the dobutamine infusion is discontinued.

The indications for early termination of dobutamine stress testing are similar to those of exercise stress testing. ST elevation and ventricular tachycardia are more likely with dobutamine stress testing than any other type of stress testing.

Typically, adverse effects requiring early termination subside within 5-10 minutes of discontinuation of the infusion (the half-life of dobutamine is 2 min). The effect of dobutamine can be reversed with beta-blockers; typically, an intravenous agent with an ultrashort half-life, such as esmolol, is used. Because most patients who undergo dobutamine stress testing have bronchospastic lung disease, beta-blockers should be used with caution.

Hemodynamic effects

A dose-related increase in both heart rate and SBP occurs with dobutamine. However, diastolic pressure falls as the dose of dobutamine increases. These hemodynamic changes are similar to those of exercise stress.

Previous
Next

Regadenoson (Lexiscan) Technique

Dosing and practical considerations

The recommended intravenous dose of regadenoson is 5 mL (0.4 mg regadenoson)

Administer regadenoson as a rapid (approximately 10 seconds) injection into a peripheral vein using a 22 gauge or larger catheter or needle. This should be followed by a 5 mL saline flush immediately after the injection of regadenoson. Administer the radionuclide myocardial perfusion imaging agent 10–20 seconds after the saline flush. The radionuclide may be injected directly into the same catheter as regadenoson.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Do not administer regadenoson if it contains particulate matter or is discolored.

Hemodynamic effects

A rapid increase in coronary blow flow of a short duration occurs when regadenoson is the agent of choice. Clinical studies showed that most patients manifested a decrease in blood pressure and an increase in heart rate within 45 minutes after administration of regadenoson.

Previous
Next

Laboratory Medicine

Laboratory tests are used to determine myocardial ischemia or risk of infarction; electrolytes, drug levels; toxicities; levels of thyroid-stimulating hormone; and BNP level.

Clinical chemistry

Clinical chemistry studies include measurements of the following:

  • Troponin-1
  • Creatine kinase
  • Myoglobin
  • Brain-type natriuretic peptide
  • Calcium
  • Magnesium
  • Potassium
  • Bicarbonate

Elevations in cardiac enzyme (troponin, creatine kinase, myoglobin) levels may indicate ischemia and MI. The extent of myocardial damage usually can be correlated to the extent of elevation in the enzyme levels. Patients are at increased risk for arrhythmia in the peri-infarct period.

BNP has predictive value especially in post MI patients and in patients with heart failure. Although preliminary and not conclusive, emerging data support the notion that an elevated BNP level may provide prognostic information on the risk of SCD, independent of clinical information and LVEF.

Severe metabolic acidosis, hypokalemia, hyperkalemia, hypocalcemia, and hypomagnesemia are some of the conditions that can increase the risk for arrhythmia and sudden death.

Metabolic and endocrine tests

Obtain levels of thyroid-stimulating hormone. Hyperthyroidism can lead to tachycardia and tachyarrhythmias. Over a period of time, it also can lead to heart failure. Hypothyroidism can lead to QT prolongation.

Therapeutic-drug monitoring and toxicology

Therapeutic drug monitoring and toxicology includes obtaining the following:

  • Drug levels (quinidine, procainamide, tricyclic antedepressants, digoxin)
  • Amitriptyline level
  • Desipramin level
  • Doxepin level
  • Imipramine level
  • Nortriptyline level
  • Serum toxicology screening

Drug (quinidine, procainamide, tricyclic antidepressants, digoxin) levels higher than the levels indicated in the therapeutic index may have a proarrhythmic effect. Subtherapeutic levels of these drugs in patients being treated for specific cardiac conditions also can lead to an increased risk for arrhythmia. Most of the antiarrhythmic medications also have a proarrhythmic effect.

Looking for drugs, such as cocaine, that can lead to vasospasm-induced ischemia is warranted if suspicion exists. Obtaining levels of drugs (antiarrhythmics) also may be warranted.

Urine Analysis

Obtain a urine toxicology screen to test for the types and approximate amounts for legal and illegal drugs that can affect heart function.

Previous
 
 
Contributor Information and Disclosures
Author

David Akinpelu, MD, FACP Emergency Medicine Attending Physician, Riverside Tappahannock Hospital/Riverside Shore Memorial Hospital, Riverside Medical Group

David Akinpelu, MD, FACP is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine, American Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Ronald J Oudiz, MD, FACP, FACC, FCCP Professor of Medicine, University of California, Los Angeles, David Geffen School of Medicine; Director, Liu Center for Pulmonary Hypertension, Division of Cardiology, LA Biomedical Research Institute at Harbor-UCLA Medical Center

Ronald J Oudiz, MD, FACP, FACC, FCCP is a member of the following medical societies: American College of Cardiology, American College of Chest Physicians, American Thoracic Society, American College of Physicians, American Heart Association

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Actelion, Bayer, Gilead, Lung Biotechnology, United Therapeutics<br/>Received research grant from: Actelion, Bayer, Gilead, Ikaria, Lung Biotechnology, Pfizer, Reata, United Therapeutics<br/>Received income in an amount equal to or greater than $250 from: Actelion, Bayer, Gilead, Lung Biotechnology, Medtronic, Reata, United Therapeutics.

Chief Editor

Eric H Yang, MD Associate Professor of Medicine, Director of Cardiac Catherization Laboratory and Interventional Cardiology, Mayo Clinic Arizona

Eric H Yang, MD is a member of the following medical societies: Alpha Omega Alpha

Disclosure: Nothing to disclose.

Additional Contributors

Justin D Pearlman, MD, ME, PhD, FACC, MA Chief, Division of Cardiology, Director of Cardiology Consultative Service, Director of Cardiology Clinic Service, Director of Cardiology Non-Invasive Laboratory, Chair of Institutional Review Board, University of California, Los Angeles, David Geffen School of Medicine

Justin D Pearlman, MD, ME, PhD, FACC, MA is a member of the following medical societies: American College of Cardiology, International Society for Magnetic Resonance in Medicine, American College of Physicians, American Federation for Medical Research, Radiological Society of North America

Disclosure: Nothing to disclose.

Acknowledgements

Javier M Gonzalez, MD Consulting Staff, Department of Cardiology, Citrus Cardiology Consultants

Javier M Gonzalez, MD is a member of the following medical societies: American College of Cardiology and American Medical Association

Disclosure: Nothing to disclose.

References
  1. Blankstein R, Cannon C, Udelson J. Update on pharmacological cardiac stress testing: efficacy, risk stratification and patient selection. Am J Med. 2014 Nov. 127(11):e16-7. [Medline].

  2. Patel JJ, Gupta A, Nanda NC. Comparison of hyperemic impedance echocardiography with dobutamine Stress Echocardiography to detect inducible myocardial ischemia: a pilot study. Echocardiography. 2016 Mar. 33 (3):416-20. [Medline].

  3. Shah BR, Cowper PA, O'Brien SM, Jensen N, Patel MR, Douglas PS, et al. Association between physician billing and cardiac stress testing patterns following coronary revascularization. JAMA. 2011 Nov 9. 306(18):1993-2000. [Medline].

  4. Pazhenkottil AP, Nkoulou RN, Ghadri JR, et al. Prognostic value of cardiac hybrid imaging integrating single-photon emission computed tomography with coronary computed tomography angiography. Eur Heart J. 2011 Jun. 32(12):1465-71. [Medline].

  5. Martin WH 3rd, Xian H, Wagner D, Chandiramani P, Bainter E, Ilias-Khan N. Arm exercise as an alternative to pharmacologic stress testing: arm exercise stress testing and outcome. Am Heart J. 2014 Feb. 167(2):169-77. [Medline].

  6. Patel K, Alattar F, Koneru J, Shamoon F. ST-elevation myocardial infarction after pharmacologic persantine stress test in a patient with Wellens' syndrome. Case Rep Emerg Med. 2014. 2014:530451. [Medline]. [Full Text].

  7. Lowes R. FDA Issues Warning on Regadenoson, Adenosine. http://www.medscape.com/viewarticle/814727. Accessed December 1, 2013. Medscape. [Full Text].

  8. FDA Safety Annoucement. FDA warns of rare but serious risk of heart attack and death with cardiac nuclear stress test drugs Lexiscan (regadenoson) and Adenoscan (adenosine). [Full Text].

  9. Zoghbi GJ, Htay T, Aqel R, Blackmon L, Heo J, Iskandrian AE. Effect of caffeine on ischemia detection by adenosine single-photon emission computed tomography perfusion imaging. J Am Coll Cardiol. 2006 Jun 6. 47(11):2296-302. [Medline].

  10. Korosoglou G, Gitsioudis G, Voss A, Lehrke S, Riedle N, Buss SJ, et al. Strain-encoded cardiac magnetic resonance during high-dose dobutamine stress testing for the estimation of cardiac outcomes comparison to clinical parameters and conventional wall motion readings. J Am Coll Cardiol. 2011 Sep 6. 58(11):1140-9. [Medline].

  11. Abe S, Takeishi Y, Chiba J, Ikeda K, Tomoike H. Comparison of adenosine and treadmill exercise thallium-201 stress tests for the detection of coronary artery disease. Jpn Circ J. 1993 Dec. 57(12):1111-9. [Medline].

  12. Beller GA. New directions in myocardial perfusion imaging. Clin Cardiol. 1993 Feb. 16(2):86-94. [Medline].

  13. Beller GA. Radionuclide perfusion imaging techniques for evaluation of patients with known or suspected coronary artery disease. Adv Intern Med. 1997. 42:139-201. [Medline].

  14. Botvinick EH. Current methods of pharmacologic stress testing and the potential advantages of new agents. J Nucl Med Technol. 2009 Mar. 37(1):14-25. [Medline].

  15. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002 Oct 2. 40(7):1366-74. [Medline]. [Full Text].

  16. Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging. 2008 May. 1(3):307-16. [Medline].

  17. Ellstead MH. Stress Testing: Principles and Practice. 4th ed. Philadelphia, Pa: FA Davis; 1995.

  18. Fletcher GF, Flipse TR, Kligfield P, Malouf JR. Current status of ECG stress testing. Curr Probl Cardiol. 1998 Jul. 23(7):353-423. [Medline].

  19. Goraya TY, Jacobsen SJ, Pellikka PA, et al. Prognostic value of treadmill exercise testing in elderly persons. Ann Intern Med. 2000 Jun 6. 132(11):862-70. [Medline].

  20. Guyton AC, Hall JE. Textbook of Medical Physiology. 9th ed. Philadelphia, Pa: 1995.

  21. Mansoor MR, Heller GV. Recent developments in the prognostic use of myocardial perfusion imaging. Curr Opin Cardiol. 1997 Nov. 12(6):571-80. [Medline].

  22. Ruf J, Paganelli F, Bonello L, et al. Spare adenosine A2 receptors are associated with positive exercise stress test in coronary artery disease. Mol Med. 2016 Jul 19. 22:[Medline].

  23. Puente-Maestu L, Palange P, Casaburi R, et al. Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. Eur Respir J. 2016 Feb. 47 (2):429-60. [Medline].

  24. Sampaio F, Lamata P, Bettencourt N, et al. Assessment of cardiovascular physiology using dobutamine stress cardiovascular magnetic resonance reveals impaired contractile reserve in patients with cirrhotic cardiomyopathy. J Cardiovasc Magn Reson. 2015 Jul 18. 17:61. [Medline].

  25. Hunter CR, Hill J, Ziadi MC, Beanlands RS, deKemp RA. Biodistribution and radiation dosimetry of (82)Rb at rest and during peak pharmacological stress in patients referred for myocardial perfusion imaging. Eur J Nucl Med Mol Imaging. 2015 Jun. 42 (7):1032-42. [Medline].

 
Previous
Next
 
Normal radionuclide uptake (dipyridamole-Cardiolite).
ECGs show a normal sinus rhythm and a sinus rhythm with a left bundle branch block.
ECG depicts electrophysiologic events of left bundle branch block.
Table 1. Findings and Likely Associated Results
Results Rest Stress Conclusion
Findings Normal Normal Blood flow to coronary artery is likely normal
Findings Normal Reversible perfusion defect Artery blockage may be present
Findings Abnormal Abnormal Heart has had prior injury, eg, previous heart attack
Previous
Next
 
 
 
Medscape Consult
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.